These trainings are offered by Qiagen, not BTEP, and are listed here for your convenience.
(Last updated March 5,2024)
- Mar. 6 @ 1 PM, New user training: Large dataset analysis and knowledge base queries using QIAGEN Ingenuity Pathway Analysis (IPA)
Register
- Mar. 7 @ 11 AM, Using COSMIC to predict, identify, and avoid mutational consequences of cancer therapies during early drug development and in patients
Register
Whether your lab is researching and developing targeted cancer therapies or you are analyzing and interpreting diagnostic tests at the point-of-care, a critical part of your workflow is understanding the structural and functional impact of cancer-related mutations.
The Catalogue Of Somatic Mutations In Cancer (COSMIC) is an expert-curated database encompassing a wide variety of somatic mutation mechanisms causing human cancer. Containing more than 24 million somatic variants with detailed information on mutation distribution, effects, and signatures, COSMIC helps users better predict the cancer-driving effects of mutations and identify available drugs that target specific variants. COSMIC continues to expand its utility with continuous updates to its Mutational Signatures, the Cancer Mutation Census, and Mutation Actionability in Precision Oncology products.
To illustrate key applications of these features, this webinar will focus on how COSMIC can be used to avoid mutational consequences in cancer drug development and to profile the mutational signatures of cancer therapies in clinical samples.
Through these clinical and discovery use cases, attendees will learn:
- How to evaluate genomic loci using the comprehensive coding and non-coding variant annotations within COSMIC
- How to integrate these variants with curated findings and summaries of mutational impact and clinical actionability
- How mutational signatures could be useful for clinical diagnosis and drug development applications now and in the future
- Mar. 14 @ 1 PM, ATCC cell line data utilization for cell line selection, validation and other applications
Register
- Mar. 21 @ 11 AM, Virtual Roundtable: Advances in Genomic Testing for Rare Disease Diagnostics: Detection, Interpretation, Access
Register
Over the past decade, whole-exome and whole-genome sequencing have transformed the diagnosis of patients with suspected rare genetic diseases. However, despite recent advancements, a large number of patients with rare genetic diseases remains undiagnosed for years because they have limited access to comprehensive genomic testing.
In this virtual roundtable of leading rare disease experts, panelists will discuss:
- The state of clinical genomic testing at their institutions.
- How recent advances in sequencing technology and data analysis, including artificial intelligence (AI), are increasing diagnostic rate.
- How barriers to patient access to testing can be removed to improve the care of all people living with rare genetic diseases.
At the NYGC, Jobanputra oversees all clinical testing at NYGC and leads a team of 16 individuals, including clinical technologists, bioinformatics scientists, and supporting staff. Jobanputra has been responsible for setting up the clinical laboratory, overseeing the validation and launch of the constitutional exome, genome, and targeted variant assays, as well as reference sequencing.She is also responsible for the validation and oversight of the oncology genome, exome, and transcriptome sequencing assays. Jobanputra’s research focuses on genomic and transcriptome studies of rare undiagnosed diseases and cancer.
- Mar. 26 @ 11 AM, Agilent Alissa to QCI Interpret: How can your lab reduce the stress and complexity of transitioning to a new clinical information platform?
Register
In 2023, Agilent announced the discontinuation of their Alissa Interpret clinical informatics platform by the end of 2024. As a result, many of their current customers need to transition to a new variant interpretation and reporting software within a tight timeframe. However, when evaluating new interpretation solutions, clinical labs must consider a variety of factors, including:
- Content quality for clinical reporting
- Flexibility to adapt current workflows to a new platform
- Retaining historical content and comments
- Ease of personnel training
In this webinar, learn about QCI Interpret, a panel- and sequencer-agnostic clinical informatics platform for NGS variant interpretation and reporting of germline and somatic tests. Our experts will address the concerns of current Alissa users and discuss what sets QCI Interpret apart from other interpretation solutions. In addition, we will show you how seamless it is to transition your historical data and comments into QCI Interpret, as well as provide a live demonstration of the industry-leading and reliable software that has been used to analyze and interpret more than 3.5 million patient test cases worldwide.
- Mar. 26 @ 1 PM, Single Cell RNA-Seq, Cell Hashing, and Spatial Transcriptomics
Register
A slide illustrating some of the many result types/graphics you will be able to generate after this training. https://qiagen.showpad.com/share/jYTCDPNfz1SdIMPQPSPYS
Description: In this training, you will learn how to analyze and interpret your own single cell RNA-seq data using QIAGEN CLC Genomics Workbench starting with either FASTQ or matrix files.
Using CLC Genomics Workbench, you will learn how to perform secondary analysis on your single cell RNA-seq data. Specifically, you will learn how to:
• Import your raw FASTQ or processed cell-matrix files.
• Use pre-configured but customizable pipelines/workflows for single cell RNA-seq data.
• Generate high resolution visuals and other files from your analysis for publications and biopharmaceutical discoveries.
o Dimension reduction (UMAP, t-SNE) plots o Differential expression table for clusters, cell types, or combination of both
o Heat map
o Dot plots
o Violin plots
• Learn how to use “Create Cell Annotations from Hashtags” for cell hashing (i.e., CITE-seq).
• Dive into spatial transcriptomic analysis, the latest feature in the single cell RNA-seq module.
- Mar. 28 @ 1 PM, Multi-omics (metabolomics, proteomics, transcriptomics) analysis using QIAGEN Ingenuity Pathway Analysis
Register
This 90-minute training session is about how QIAGEN Ingenuity Pathway Analysis (IPA) allows visualization of molecular intricacy and variations at multiple levels such as transcriptome, proteome, and metabolome. Through a series of brief technical vignettes, it is demonstrated how to:
· Generate associations among molecular signatures obtained via integrating multi-omics data
· Extract mechanisms from multi-omics data for precision medicine
· Disease stratification based on multi-omics profiles
· Map disease networks among targets and indications